GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Debt-to-Revenue

CG Oncology (CG Oncology) Debt-to-Revenue : 0.19 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

CG Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.22 Mil. CG Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.18 Mil. CG Oncology's annualized Revenue for the quarter that ended in Mar. 2024 was $2.12 Mil. CG Oncology's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.19.

CG Oncology Debt-to-Revenue Historical Data

The historical data trend for CG Oncology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Debt-to-Revenue Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Revenue
1.46 83.48 2.26

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial N/A - N/A 115.25 0.19

Competitive Comparison of CG Oncology's Debt-to-Revenue

For the Biotechnology subindustry, CG Oncology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where CG Oncology's Debt-to-Revenue falls into.


CG Oncology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

CG Oncology's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.217 + 0.244) / 0.204
=2.26

CG Oncology's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.22 + 0.184) / 2.116
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

CG Oncology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of CG Oncology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Debt-to-Revenue
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024